Exhibits several functions, including DNA binding activity; DNA-binding transcription factor activity; and steroid hormone receptor activity. Involved in regulation of cell population proliferation. Localizes to several cellular components, including glutamatergic synapse; postsynaptic density, intracellular component; and presynaptic active zone cytoplasmic component. Human ortholog(s) of this gene implicated in autosomal dominant pseudohypoaldosteronism type 1 and pseudohypoaldosteronism. Orthologous to human NR3C2 (nuclear receptor subfamily 3 group C member 2); PARTICIPATES IN aldosterone signaling pathway; amiloride pharmacodynamics pathway; bendroflumethiazide pharmacodynamics pathway; INTERACTS WITH (+)-schisandrin B; (S)-nicotine; 11-deoxycorticosterone.
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of NR3C2 protein more ...
Metribolone binds to and results in decreased activity of NR3C2 protein, Metribolone inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
acephate inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], acephate inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
alachlor inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], alachlor inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
Aldosterone inhibits the reaction [TSG101 protein binds to NR3C2 protein], FR 180204 inhibits the reaction [Aldosterone results in increased phosphorylation of NR3C2 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA
Atrazine metabolite inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], Atrazine metabolite inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
bifenthrin inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], bifenthrin inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA
cypermethrin inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], cypermethrin inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
Dichlorodiphenyl Dichloroethylene inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], Dichlorodiphenyl Dichloroethylene inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
DDT inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], DDT inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
Dimethoate inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], Dimethoate inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
Angiotensin-Converting Enzyme Inhibitors results in decreased expression of NR3C2 mRNA, Angiotensin-Converting Enzyme Inhibitors results in decreased expression of NR3C2 protein
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA
[fipronil co-treated with DEET] results in decreased expression of NR3C2 mRNA, fipronil inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
[Fludrocortisone binds to and results in increased activity of NR3C2 protein] which results in decreased abundance of Hydrocortisone, [Fludrocortisone binds to and results in increased activity of NR3C2 protein] which results in decreased expression of POMC protein
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA, [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 protein
Methoxychlor inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], Methoxychlor inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA
Permethrin inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], Permethrin inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR3C2 mRNA
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of NR3C2 protein more ...
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA
Spironolactone inhibits the reaction [Aldosterone affects the ubiquitination of NR3C2 protein], Spironolactone inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
terbutylazine inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], terbutylazine inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NR3C2 mRNA
Zineb inhibits the reaction [Aldosterone affects the localization of NR3C2 protein], Zineb inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
